Literature DB >> 8306317

Loss of heterozygosity on chromosome 13 is common only in the biologically more aggressive subtypes of ovarian epithelial tumors and is associated with normal retinoblastoma gene expression.

T M Kim1, W F Benedict, H J Xu, S X Hu, J Gosewehr, M Velicescu, E Yin, J Zheng, G D'Ablaing, L Dubeau.   

Abstract

We examined the frequencies of loss of heterozygosity on chromosome 13 in 77 primary ovarian epithelial tumors subdivided into cystadenomas, tumors of low malignant potential, low grade carcinomas, and high grade carcinomas. Such losses were found in approximately 50% of high grade carcinomas but were not detected in any of the other tumor subtypes (P < 0.0001), suggesting a strong association between these abnormalities and the high grade carcinoma phenotype. The tumors were also examined for abnormalities in expression of the retinoblastoma susceptibility gene (RB). This was assessed by immunohistochemical staining of archival tumor sections with a polyclonal antibody directed against both the phosphorylated and the underphosphorylated forms of the RB protein. Most of the tumors, including those with allelic deletions on chromosome 13, showed normal RB nuclear protein staining patterns. We conclude that loss of RB expression is not a frequent event in primary ovarian carcinomas and that this gene is probably not the target of the frequent allelic deletions on chromosome 13 found in high grade ovarian carcinomas.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8306317

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

Review 1.  Role of p53 and Rb in ovarian cancer.

Authors:  David C Corney; Andrea Flesken-Nikitin; Jinhyang Choi; Alexander Yu Nikitin
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

2.  Differential retinoblastoma protein expression in neuroendocrine tumors of the lung. Potential diagnostic implications.

Authors:  P T Cagle; A K el-Naggar; H J Xu; S X Hu; W F Benedict
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

3.  Mutation screening analysis of the retinoblastoma related gene RB2/p130 in sporadic ovarian cancer and head and neck squamous cell cancer.

Authors:  A J Alvi; R Hogg; J S Rader; M J Kuo; E R Maher; F Latif
Journal:  Mol Pathol       Date:  2002-06

4.  Genomic changes in glioblastoma cell lines detected by comparative genomic hybridization.

Authors:  V S Venkatraj; M Begemann; A Sobrino; J N Bruce; I B Weinstein; D Warburton
Journal:  J Neurooncol       Date:  1998-01       Impact factor: 4.130

5.  Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer.

Authors:  A P M Jongsma; J M J Piek; R P Zweemer; R H M Verheijen; J W T Klein Gebbinck; G J van Kamp; I J Jacobs; P Shaw; P J van Diest; P Kenemans
Journal:  Mol Pathol       Date:  2002-10

Review 6.  The genetic analysis of ovarian cancer.

Authors:  A N Shelling; I E Cooke; T S Ganesan
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

7.  Evidence for divergence of DNA copy number changes in serous, mucinous and endometrioid ovarian carcinomas.

Authors:  J Tapper; R Bützow; T Wahlström; M Seppälä; S Knuutila
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Evidence for the presence of two tumour-suppressor genes for hepatocellular carcinoma on chromosome 13q.

Authors:  T Kuroki; Y Fujiwara; S Nakamori; S Imaoka; T Kanematsu; Y Nakamura
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

9.  Loss of heterozygosity in sporadic breast tumours at the BRCA2 locus on chromosome 13q12-q13.

Authors:  A M Cleton-Jansen; N Collins; S R Lakhani; J Weissenbach; P Devilee; C J Cornelisse; M R Stratton
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

10.  WAF1/CIP1 structural abnormalities do not contribute to cell cycle deregulation in ovarian cancer.

Authors:  M Wan; K F Cofer; L Dubeau
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.